NDAORALTABLET, EXTENDED RELEASE
Approved
Jan 2020
Lifecycle
Peak
Competitive Pressure
0/100
Data completeness
5/8 — Partial
TRIJARDY XR (empagliflozin, linagliptin, metformin hydrochloride) by Boehringer Ingelheim is dipeptidyl peptidase 4 inhibitors [moa]. Approved for dipeptidyl peptidase 4 inhibitor [epc]. First approved in 2020.
Drug data last refreshed 8h ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
TRIJARDY XR is a fixed-dose combination tablet combining empagliflozin (SGLT2 inhibitor), linagliptin (DPP-4 inhibitor), and metformin hydrochloride (biguanide) for oral use. It is indicated for type 2 diabetes mellitus management in patients requiring triple-agent glycemic control. The triple mechanism addresses multiple pathways: SGLT2 inhibition increases urinary glucose excretion, linagliptin enhances incretin signaling, and metformin reduces hepatic glucose production.
$76MPart D
Peak11.3 years to LOEAt peak lifecycle with $76M in Part D spending and 80K+ claims, TRIJARDY XR represents a stable but modest revenue contributor in a crowded category; commercial teams are focused on retention rather than growth.
Mechanism of Action
Dipeptidyl Peptidase 4 Inhibitors
Pharmacologic Class:
Dipeptidyl Peptidase 4 Inhibitor
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
TRIJARDY XR offers stable career opportunities in a mature, established franchise within Boehringer Ingelheim's diabetes portfolio, though limited growth trajectory. Roles focus on market share defense, managed care negotiations, and managed portfolio optimization rather than expansion or innovation.
Brand Manager
Worked on TRIJARDY XR at Boehringer Ingelheim? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.